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Few studies focused on the association of SORL1 with the age at onset (AAO) of Alzheimer disease (AD). This study investigated
the association of 43 SNPs in SORL1 with the AAO of AD by using the Kaplan-Meier survival analysis and the Cox proportional
hazards model in SAS version 9.2 and linear regression model in PLINK software (791 AD patients and 782 controls). Both logrank
test and Cox regression model showed that five SNPs (rs1784934, rs676759, rs560573, rs593769, and rs11218313) were associated
with the AAO of AD in the male sample, while one SNP (rs17125558) was associated with the AAO of AD in the female sample
(𝑃 < 0.05). SNP rs560573, previously associated with the risk of late-onset AD, showed the most association with the AAO in the
male sample (𝑃 = 0.0077 for logrank test and 𝑃 = 0.0117 in the Cox model). The mean AAO was approximately 2.5 years earlier
in individuals who were homozygous for the minor allele compared with those who had at least one major allele. Linear regression
model showed that rs2282649 and rs726601 were associated with AAO in the whole sample (𝑃 = 0.0374 and 0.0367, resp.). These
findings provide evidence of several genetic variants in SORL1 influencing the AAO of AD.
1. Introduction
Alzheimer disease (AD) is themost common form of demen-
tia. Most often, AD is diagnosed in people over 65 years of
age, although the less-prevalent early-onset Alzheimer’s can
occur much earlier [1]. In the United States, the prevalence
of AD in 2000 was estimated to be about 1.6% in the 65–74
age group, with the rate increasing to 19% in the 75–84 age
group and to 42% in the greater than 84 age group [2]. The
World Health Organization estimated that, in 2005, 0.379%
of people worldwide had dementia, and the prevalence would
increase to 0.441% in 2015 and to 0.556% in 2030 [3]. Another
study estimated that, in 2006, 0.40% of the world population
(about 26.6 million) was afflicted by AD, which is predicted
to affect 1 in 85 people globally by 2050 [4].
In addition to the disease risk, age at onset (AAO) of AD
is also genetically influenced with an estimated heritability
of about 42% [5, 6]. Genetic effects account for 57%–78%
of the variance of AAO [7], while twin studies suggest that
the heritability of AD exceeds 60% [8]. AD has a strong
genetic predisposition (60–80% of the attributable risk) [9].
The sortilin-related receptor (SORL1) gene is located at
11q23.2-q24.2 and is expressed as a 10.5 kb transcript in brain,
spinal cord, and testis [10]. Rogaeva et al. [11] reported that
inherited variants of the SORL1 neuronal sortilin-related
receptor were associated with late-onset AD. Lee et al. [12]
reported associations between various SNPs and haplotypes
in the SORL1 gene and AD among a total of 296 AD patients
comprising 3 cohorts of African American, Caribbean His-
panic, and non-Hispanic white individuals. Their results
suggested extensive allelic heterogeneity in SORL1, with
specific SNPs associated with specific groups. Cellini et al.
[13] concluded that their findings confirmed the association
between SORL1 and late-onset AD. Reitz et al. [14] also
reported that their findings provided confirmatory evidence
of the association of multiple SORL1 variants with AD risk.
However, few studies have focused on the association of
SORL1 with the AAO of AD [12, 15]. This study explored
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Table 1: Descriptive characteristics of cases and controls.
Variable Total patients Male patients Female patients Control
Sample size (𝑛) 791 334 457 782
Mean AAO (years ± SD) 72.3 (±8.5) 71.8 (±8.3) 72.6 (±8.6) NA
Median AAO (years) 73 73 73 NA
Range of age at onset (years) 40–97 44–90 40–97 NA
Mean age at entry (years ± SD) 77.6 (±8.6) 77.5 (±8.4) 78.2 (±8.7) 73.4 (±7.9)
Median age at entry (years) 79 79 79 79
Range of age at entry (years) 43–100 49–94 43–100 48–94
the association of SORL1 with the AAO of AD in a Canadian
sample by using the Kaplan-Meier survival analysis, the Cox
proportional hazards model, and linear regression model.
2. Materials and Methods
2.1. Subjects. Seven hundred and ninety-one patients with
AD and 782 controls with complete genotype and phe-
notype information in a Canadian sample were selected
from the Multi-Site Collaborative Study for Genotype-
Phenotype Associations in Alzheimer’s Disease and the Lon-
gitudinal Follow-Up of Genotype-Phenotype Associations
in Alzheimer’s Disease and the Neuroimaging Component
of Genotype-Phenotype Associations in Alzheimer’s Disease
(dbGaP Study Accession: phs000219.v1.p1). The details about
these subjects were described elsewhere [16, 17]. Genotyping
was conducted using the Affymetrix 500K Set comprising
the Mapping250K Nsp and Mapping250K Sty Arrays (total
262,264 SNPs). We investigated the genetic associations of 43
single-nucleotide polymorphisms (SNPs) within the SORL1
gene with the AAO of AD.
2.2. Statistical Methods. Hardy-Weinberg equilibrium was
tested for all SNPs using the controls by using Haploview
software [18]. Then, minor allele frequency (MAF) was
determined for each SNP. The assessment of the association
between genotypes of each SNP and AAO was initially
performed using the logrank test (a nonparametric test)
in Kaplan-Meier (KM) survival analysis. The KM survival
curves were used to plot the survival function. When a
significant value was obtained in the KM testing, the Cox
proportional hazards model (a semiparametric model) was
used to confirm the findings of KM analysis. Hazard ratio
(HR) and 95% CI were calculated with Cox proportional
hazards analysis of SNPs. Descriptive statistics for AAO
and survival analyses were conducted with SAS statistical
software, version 9.2 (SAS Institute, Cary, NC, USA).
To test for association with AAO as a quantitative trait,
linear regression analysis was performed by PLINK 1.07
[19] to obtain the regression coefficient (𝛽) and Wald test
asymptotic 𝑃 value. For statistical significance, empirical 𝑃
values were generated by 100,000 permutation tests using
Max (T) permutation procedure implemented in PLINK.
This procedure allows calculation of the pointwise estimates
of an individual SNP’s significance (empirical pointwise 𝑃
values). Pairwise linkage disequilibrium (LD) statistics (𝐷󸀠)
were assessed for the controls using Haploview [18]. We
identified haplotype blocks based on solid spine of LD using
Haploview [18]. Then we chose several SNPs within blocks
including the associated SNPs for further analyses. Haplotype
analysis based on a slide-window was performed using
PLINK. To perform gene-based analysis, we constructed SNP
sets based on haplotpye blocks; then we perform set-based
tests using PLINK.
3. Results
3.1. Subjects Characteristics. Thedemographic characteristics
of the subjects in the study are detailed in Table 1. The mean
AAO for the cases was 72.3 years (71.8 years for the males and
72.6 years for the females, resp.). The mean age at entry into
studywas 77.6 years for cases (77.5 years for themales and 78.2
years for the females, resp.) and 73.4 years for the controls.
3.2. Survival Analyses. Of the 43 SNPs, none was associated
with the AAO of AD in the whole sample using the logrank
test. Interestingly, five SNPs were associated with the AAO of
AD in the male sample, while one SNP was associated with
the AAO of AD in the female sample (𝑃 < 0.05). The results
of the top 6 associated SNPs based on the logrank test are
summarized in Table 2. All 6 SNPs were in Hardy-Weinberg
equilibrium in the controls. The most statistically significant
associated SNPs were rs560573 (𝑃 = 0.0077) and rs593760
(𝑃 = 0.0077) in the male sample.
Cox proportional models further confirmed the associa-
tions of these 6 SNPs (Table 3). SNPs rs560573 and rs593769
showed the most association with AAO in the Cox model
with HR = 1.47 (95% CI = 1.09–1.97). The mean AAO
was approximately 2.5 years earlier for individuals (TT for
rs560573 and CC for rs593769) who were homozygous for
theminor allele compared with those (AA or AT for rs560573
and CT + TT for rs593769) who had at least one major allele.
Figure 1 shows the survival function for different genotypes
of SNP rs560573. The median of AAO was 71 years for
individuals with TT genotype and 73 years for individuals
with AA or AT genotypes.
3.3. Linear Regression Analysis. The results of linear regres-
sion model are summarized in Table 4. Single-marker analy-
sis showed that rs2282649 and rs726601 were associated with
AAO in the whole sample (𝑃 = 0.0374 and 0.0367, resp.)
and rs11218313 was associated with AAO in the male sample
(𝑃 = 0.0318). For the rs11218313 (𝛽 = 2.82), the mean AAO in
malewas approximately 2.8 years earlier for theminor alleleG
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Table 2: Top 6 SNPs associated with the age at onset of Alzheimer’s disease using the logrank test.
SNP Position A1a MAFb HWEc Logrank-alld Logrank-malee Logrank-femalef
rs1784934 121467284 C 0.36 0.35 0.288 0.040 0.96
rs676759 121488556 G 0.40 0.49 0.154 0.008 0.933
rs560573 121490175 T 0.39 0.59 0.176 0.0077 0.836
rs593769 121493294 C 0.39 0.84 0.152 0.0077 0.933
rs11218313 121512162 G 0.09 0.38 0.185 0.0317 0.89
rs17125558 121003094 T 0.03 0.71 0.0715 0.758 0.039
aMinor allele; bminor allele frequency; cHardy-Weinberg equilibrium 𝑃 value; d𝑃 value was based on logrank test for the whole sample; e𝑃 value was based on
the logrank test for the males; f𝑃 value was based on the logrank test for the females.
Table 3: Top 6 SNPs associated with the age at onset of Alzheimer’s disease using the Cox proportional hazards model.
SNP Male Mean HRa 95% CIb 𝑃 Female Mean HR 95% CI 𝑃
rs1784934
AA 42 70.6 1.39 1.00–1.93 0.049 59 72.9 1.01 0.76–1.32 0.962
AG + GG 292 72.0 1.00 398 73.5 1.00
rs676759
GG 53 69.8 1.46 1.09–1.97 0.0121 65 73.4 0.99 0.76–1.29 0.937
AA + AG 281 72.2 392 72.5 1.00
rs560573
TT 53 69.7 1.47 1.09–1.97 0.0117 63 73.5 0.97 0.74–1.27 0.845
AA + AT 281 72.2 1.00 394 72.4 1.00
rs593769
CC 53 69.7 1.47 1.09–1.97 0.0117 65 73.4 0.99 0.76–1.29 0.937
CT + TT 281 72.2 1.00 392 72.5 1.00
rs11218313
AG + GG 45 74.2 0.72 0.53–0.99 0.0459 80 72.6 0.98 0.77–1.26 0.897
AA 289 71.4 1.00 377 72.6 1.00
rs17125558
CT + TT 14 71.4 1.08 0.63–1.85 0.772 25 70.1 1.50 1.00–2.25 0.0494
CC 320 71.8 1.00 432 72.7 1.00
aHR refers to hazard ratio; bCI refers to confidence interval.
Table 4: Association results for 8 SNPs and the age at onset of Alzheimer’s disease using the linear regression model.
SNP Position A1a 𝛽-allb 𝑃-allc EMP1d 𝛽-malee 𝑃-malef EMP-maleg 𝛽-femaleh 𝑃-femalei EMP-femalej
rs1784934 121467284 C 0.08 0.865 0.865 −0.71 0.296 0.295 0.65 0.261 0.258
rs676759 121488556 G 0.14 0.749 0.752 −0.78 0.240 0.242 0.85 0.144 0.147
rs560573 121490175 T 0.13 0.764 0.767 −0.77 0.238 0.24 0.85 0.148 0.15
rs593769 121493294 C 0.12 0.784 0.788 −0.79 0.223 0.225 0.83 0.152 0.157
rs11218313 121512162 G 0.96 0.225 0.225 2.82 0.0326 0.0318 −0.09 0.93 0.935
rs2282649 121608249 T 0.97 0.0394 0.0374 0.67 0.359 0.365 1.15 0.0636 0.0637
rs726601 121610698 T 0.96 0.0382 0.0367 0.77 0.287 0.296 1.06 0.083 0.0844
rs17125558 121003094 T −1.78 0.648 0.653 −0.46 0.881 0.883 −2.61 0.67 0.657
aMinor allele; b𝛽 refers to the regression coefficient of the linear regression for all patients; c𝑃 value refers to the Wald test asymptotic 𝑃 value for all patients;
dempirical 𝑃 value for all patients generated by 100,000 permutation tests using Max (T) permutation procedure; e𝛽 refers to the regression coefficient of the
linear regression for male patients; f𝑃 value refers to the Wald test asymptotic 𝑃 value for male patients; gempirical 𝑃 value for male patients generated by
100,000 permutation tests using Max (T) permutation procedure; h𝛽 refers to the regression coefficient of the linear regression for female patients; i𝑃 value
refers to the Wald test asymptotic 𝑃 value for female patients; jempirical 𝑃 value for female patients generated by 100,000 permutation tests using Max (T)
permutation procedure.
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Table 5: Haplotype analysis for the whole sample.
Haplotype Frequencya 𝛽b 𝑃 valuec
rs2282648 rs2282649
T T 0.30 0.97 0.0394
T C 0.02 −0.48 0.744
C C 0.68 −0.89 0.0554
rs2282649 rs726601
T T 0.29 1.03 0.0294
C T 0.02 −0.30 0.842
C C 0.69 −0.91 0.0502
aHaplotype frequency in the sample.
b
𝛽 refers to the regression coefficient of the linear regression.
c

























Figure 1: Survival function by genotype of rs560573 0 = TT
Genotype, 1 = AA + AT Genotypes.
compared to major allele. All 3 SNPs had empirical pointwise
𝑃 values < 0.05 using a permutation procedure (Table 4).
Using Haploview software, we identified 4 haplotype
blocks for 43 SNPs. Haplotype analyses for the whole sample
(Table 5) showed that the T-T haplotype from rs2282648 and
rs2282649 (𝐷󸀠 = 1) was associated with AAO (𝑃 = 0.0394),
and the T-T haplotype from rs2282649 and rs726601 (𝐷󸀠 =
0.98) was associated with AAO (𝑃 = 0.0294). Furthermore,
haplotype analyses for the male sample (Table 6) showed that
the C-G haplotype from rs668387 and rs12218313 (D󸀠 = 1) was
associated with AAO (𝑃 = 0.0326), and the C-G haplotype
from rs1218313 and rs626885 (D󸀠 = 0.91) was associated with
AAO (𝑃 = 0.0326).
Based on the 4 haplotype blocks, we built 4 set SNPs. We
performed set-based tests using PLINK for the whole sample
and also for the male sample. We did not find any significant
associations for the set-based analyses (data not shown).
Table 6: Haplotype analysis for the male sample.
Haplotype Frequencya 𝛽b 𝑃 valuec
rs668387 rs11218313
C G 0.08 2.82 0.0326
T A 0.45 −0.28 0.66
C A 0.47 −0.35 0.51
rs11218313 rs626885
A C 0.43 −0.09 0.878
C G 0.07 2.82 0.0326
A G 0.5 −0.56 0.38
aHaplotype frequency in the sample.
b
𝛽 refers to the regression coefficient of the linear regression.
c
𝑃 value for the haplotype.
4. Discussion
In the present study we explored the association of 43 SNPs
in the SORL1 gene with the AAO of AD by using the Kaplan-
Meier survival analysis, the Cox proportional hazard model,
and the linear regression model. Using the Kaplan-Meier
survival analysis and Cox proportional hazard we found that
five SNPs were significantly associated with the AAO of AD
in themale sample and one SNPwas associatedwith theAAO
of AD in the female sample (𝑃 < 0.05). Linear regression
model showed that two SNPs (rs2282649 and rs726601) were
associatedwithAAO in thewhole sample. SNP rs11218313was
associated with AAO in the male sample using logrank test
and Cox model was also associated with AAO in the male
sample in the linear model. Haplotype analyses in the linear
model further supported the associations of single-marker
analyses.
It has been reported that SORL1 gene is consistently
downregulated approximately 2-fold in lymphoblasts from
patients with AD, and the structure and function of SORL1
as a mosaic ApoE receptor strongly suggest that it plays a
role in AD [20]. Sager et al. [21] also found a correlation
between decreased SORL1 expression and impaired cognitive
function among 34 individuals, including 10 patients with
AD, 15 with mild cognitive impairment, and 9 controls,
suggesting that decreased SORL1 expression reflects cognitive
performance and may predispose individuals with mild
cognitive impairment to the development of AD.
Several previous studies have reported that SORL1 gene
is associated with the risk of AD [11, 12, 14]; however, few
studies have focused on the association of SORL1 with the
AAO of AD. Lee et al. [12] examined the associations of
7 SNPs in SORL1 gene with the AAO of AD and found that
2 SNPs (rs536360 and rs556349) were associated with the
AAO of AD. Another study [15] investigated the associa-
tion of 4 SORL1 genetic variants (rs2070045, SORL1-18ex26,
rs3824968, and rs1010159) with the AAO of AD and found
that SORL1-18ex26 was associated with an earlier AAO of
AD in a German population. In the present study, of the
43 SNPs, none was associated with the AAO of AD in the
whole sample using the logrank test; however, two SNPs were
associated with AAO in the whole sample in the linearmodel.
Furthermore, we found that five SNPs (rs1784934, rs676759,
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rs560573, rs593769, and rs11218313) were statistically signifi-
cantly associatedwith theAAOofAD in themale sample, and
one SNP (rs17125558) was associated with the AAO of AD in
the female sample (𝑃 < 0.05) using survival analyses. Several
studies examined rs560573 with the risk of AD [11, 12, 14, 22,
23] and one study found that rs560573was associatedwith the
risk of AD [23]. Previous studies did not find the associations
of other SNPs (rs676759, rs593769, rs11218313, and rs17125558)
with the risk of AD [22].
There are a number of strengths in this study. First,
our sample size was relatively large for this type of study.
Second, we used the logrank test to examine the association
with the AAO and further confirmed the results using
the Cox proportional model. Furthermore, we conducted
linear regression analyses. In addition, we detected gender
differences. We also realized some limitations in this study.
First, our current findings might be spurious or subject to
type I error. Second, these findings need to be replicated in
additional samples.
5. Conclusions
Our results demonstrate that genetic variants in SORL1 gene
are associated with the AAO of AD.These findings may serve
as a resource for replication in other populations. Future
functional study of this gene may help to better characterize
the genetic architecture of the AAO of AD.
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